Command Palette

Search for a command to run...

Clinical Trials · NCT04152915

A Research Study Looking at Similarity Between Once-weekly Semaglutide Versions for Different Injection Pens

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
68
Start date
Nov 2019
Locations
1 site, Germany
Primary endpoint
AUC0-last,sema,1mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after one dose of s.c. semaglutide 1 mg administration following a 6-week dose escalation period
View Semaglutide compound reference